Is it worth buying Jazz Pharmaceuticals stock at a price of $138.78? If this question is on your mind, make sure to check out the fundamentals of this Pharmaceutical mid-cap company:
-
Jazz Pharmaceuticals has logged a -11.0% 52 week change, compared to 5.0% for the S&P 500
-
JAZZ has an average analyst rating of buy and is -30.89% away from its mean target price of $200.81 per share
-
Its trailing earnings per share (EPS) is $-2.55, which brings its trailing Price to Earnings (P/E) ratio to -54.4. The Health Care sector's average P/E ratio is 24.45
-
The company's forward earnings per share (EPS) is $20.2 and its forward P/E ratio is 6.9
-
The company has a Price to Book (P/B) ratio of 2.5 in contrast to the Health Care sector's average P/B ratio is 4.16
-
The current ratio is currently 2.8, which consists in its liquid assets divided by any liabilities due within in the next 12 months
-
JAZZ has reported YOY quarterly earnings growth of 175.7% and gross profit margins of 0.9%
-
The company's free cash flow for the last fiscal year was $1.27 Billion and the average free cash flow growth rate is 13.1%
-
Jazz Pharmaceuticals's revenues have an average growth rate of 14.1% with operating expenses growing at 17.0%. The company's current operating margins stand at 14.0%